Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21290263 | 0.88 | TAAR1 (0.78) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL21290839 | 0.88 | TAAR1 (0.78) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL15679325 | 0.88 | TAAR1 (0.78) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28945890 | 0.85 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28945878 | 0.83 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL21282227 | 0.82 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL30487344 | 0.81 | TAAR1 (0.67) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL29140408 | 0.80 | TAAR1 (0.66) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL29140409 | 0.80 | TAAR1 (0.66) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903730 | 0.79 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220062229-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11129807-B2 | Methods of treating schizophrenia | SUNOVION PHARMACEUTICALS INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200129477-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3252057-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2507245-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20220062229-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | TAAR1 755/4885HTR1A 270/4885DRD2 292/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20200129477-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | TAAR1 755/4885HTR1A 270/4885DRD2 292/4885 |
| US-11129807-B2 | Methods of treating schizophrenia | CHAT, GAP43, GRIN2A | TAAR1 755/4885HTR1A 270/4885DRD2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.